Use of other diabetes drugs (including sulfonamides, alpha glucosidase inhibitors, thiazolidinediones and DPP-4 inhibitors, GLP-1 analogues, SGLT2 inhibitors) was rare (1.9% in persons with AD, 2.2% in persons without AD) at the beginning of the follow-up but increased over 10-fold until the end of the follow-up (26.6% in AD and 31.5% in non-AD cohort, respectively) (Fig. 2D). Here, GCG is linked to Alzheimer disease.